Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib

Kenichiro Kudo; Keita Kawakado; Tomoka Kawajiri; Tatsuya Nishi; Go Makimoto; Tomoki Tamura; Shoichi Kuyama; Mitsune Tanimoto

doi:10.2169/internalmedicine.4449-20

Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib

Kenichiro Kudo, Keita Kawakado, Tomoka Kawajiri, Tatsuya Nishi, Go Makimoto, Tomoki Tamura, Shoichi Kuyama, Mitsune Tanimoto

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutationpositive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.

Original language	English
Pages (from-to)	1739-1740
Number of pages	2
Journal	Internal Medicine
Volume	59
Issue number	14
DOIs	https://doi.org/10.2169/internalmedicine.4449-20
Publication status	Published - Jul 15 2020
Externally published	Yes

Keywords

Brain metastasis
Dacomitinib
Non-small cell lung cancer

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.4449-20

Cite this

@article{97b742a261254e3a80ba6c4ca797cade,

title = "Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib",

abstract = "The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutationpositive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.",

keywords = "Brain metastasis, Dacomitinib, Non-small cell lung cancer",

author = "Kenichiro Kudo and Keita Kawakado and Tomoka Kawajiri and Tatsuya Nishi and Go Makimoto and Tomoki Tamura and Shoichi Kuyama and Mitsune Tanimoto",

year = "2020",

month = jul,

day = "15",

doi = "10.2169/internalmedicine.4449-20",

language = "English",

volume = "59",

pages = "1739--1740",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "14",

}

TY - JOUR

T1 - Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib

AU - Kudo, Kenichiro

AU - Kawakado, Keita

AU - Kawajiri, Tomoka

AU - Nishi, Tatsuya

AU - Makimoto, Go

AU - Tamura, Tomoki

AU - Kuyama, Shoichi

AU - Tanimoto, Mitsune

PY - 2020/7/15

Y1 - 2020/7/15

N2 - The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutationpositive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.

AB - The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutationpositive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.

KW - Brain metastasis

KW - Dacomitinib

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85088276498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088276498&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.4449-20

DO - 10.2169/internalmedicine.4449-20

M3 - Article

C2 - 32296006

AN - SCOPUS:85088276498

SN - 0918-2918

VL - 59

SP - 1739

EP - 1740

JO - Internal Medicine

JF - Internal Medicine

IS - 14

ER -

Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this